VEGFA and hepatocellular carcinoma: IMbrave150 was a randomized Phase III study in which 501 patients with unresectable HCC were randomly assigned, in a 2:1 ratio, to receive either atezolizumab plus bevacizumab or sorafenib (a standard first-line anti-VEGF treatment).